American trade negotiators tried to break local biotech CSL’s control of the Australian blood plasma market, in a move that chairman Brian McNamee says helped spur the company to transform into a global powerhouse.
Newly released Howard government cabinet documents from 20 years ago reveal the pressure the United States placed on Australia to open up CSL’s exclusive contract with the federal government and Red Cross for plasma fractionation services.
Loading...
John Kehoe is economics editor at Parliament House, Canberra. He writes on economics, politics and business. John was Washington correspondent covering Donald Trump’s first election. He joined the Financial Review in 2008 from Treasury. Connect with John on Twitter. Email John at jkehoe@afr.com
